The monitoring of chimerism after allogeneic stem cell transplantation (SCT) is indispensable because it can enable a prompt therapeutic intervention for early relapse or rejection. Moreover, chimerism analysis may be a valuable alternative in monitoring minimal residual disease. 1 The short tandem repeat (STR) markers have been increasingly used because they are highly polymorphic between individuals, and the STR assay produces quantitative results using fluorescence-labeled primers and a capillary electrophoresis system. However, a recent study highlighted potential problems of the STR assay showing poor precision and a relatively lower sensitivity, particularly when the target DNA content is low and degraded. 2 In addition, there were no common guidelines for interpreting the STR assays with respect to the clinical response. A study on the imprecision of seven STRs (D7S820, D8S1179, D16S539, D18S51, D21S11, TH01 and TPOX) using mixed blood cells at various concentrations showed that the imprecision ranged from 5.4% for TPOX to 12% for D7S820, and it was inversely related to the proportion of the concentration of the cell mixtures. A careful approach and consideration will be needed because imprecision can potentially be high, particularly with a lower proportion of donor cells. 2 To circumvent these problems, six mitochondrial DNA (mtDNA) minisatellite (mtMS) markers based on our recent report 3 and other publication regarding mtDNA genetic diversity among Korean 4 were developed to monitor the extent of donor cell engraftment in SCT recipients Letters to the Editor and to evaluate their informativeness and sensitivity compared with the nuclear DNA markers.
Nucleated animal cells contain approximately 1000 mitochondria with each containing 2-10 mtDNA. Therefore, a typical differentiated cell has approximately 3000 copies of mtDNA. 5 The mtDNA control region includes two hypervariable regions (HV1 and HV2), so called because of their high incidence of nucleotide variations. Many mtDNA length heteroplasmies (mtMS) are localized in the HV2 homopolymeric C (poly-C) tract, which lies between nucleotide positions (np) 303-315. In this paper, the length heteroplasmic sequences are abbreviated as 303 CCCCCCCTCCCCC 315 as 7CT5C (303 poly-C). Another poly-C tract variant is located between np 16184-16193 ( 16184 CCCCCTCCCC 16193 , 5CT4C) (16184 poly-C) in the HV1 region. During the construction of the Korean mtDNA database, all Koreans were found to display length heteroplasmy in both HV1 and HV2, and a high level of length heteroplasmy in the poly-C-tract of HV2. Poly-C length heteroplasmy profiling in hematopoietic tissues after allogeneic SCT may also be used to quantitatively analyze chimerism. Fifty-five to 60% of genetic alterations in CD34 þ cells, T cells and B cells were length changes in the homopolymeric C tract at np 303-315 in HV2. 6 Therefore, heterogeneity of the mtDNA sequence in normal adult CD34 þ cells might have implications such as, a natural genetic 'marker' of hematopoietic progenitors and stem cells to estimate the number of active stem cells in the steady state. 7 The patterns of mutations that have accumulated over time along the transmission of the mtDNA lineage give rise to differences between individuals, and have become the basis for forensic discrimination. 4 Six candidate mtMS markers were selected through the results of a baseline study on the mtDNA genetic diversity in Korean population. The selected mtMS markers were evaluated using clinical samples and in vitro mixing to test the informativeness, sensitivity and precision (Supplementary Figure 1) . Twentyseven patients aged 1-33(19 males, eight females) with hematological malignancies were enrolled in this study. Ten patients with acute lymphocytic leukemia, 12 with acute myelocytic leukemia, two with aplastic anemia and three with chronic myeloproliferative disorders were examined (Supplementary Table 1 ). The Institutional Review Board of the Chonnam National University Hwasun Hospital (Hwasun, Korea) approved the study protocols.
A total of 90 mtDNA polymorphic sites from 70 Korean donors were identified in the control region of the mtDNA. Three types of mtDNA alterations were found, base substitutions and small deletions/insertions as well as length heteroplasmies in the np 303-315 poly-C, np 514-523 (CA) 5 repeats and np 16184-16193 poly-C regions. A nucleotide substitution rather than insertion/deletion accounts for the majority pattern of the nucleotide changes. The transition type is more prevalent than the transversion type and insertion/deletion. The frequencies of the base substitution types were different in the HV1 and HV2 regions. The transitions constituted 83% of the base substitutions types in the HV1 region. Among all the changes, the major patterns of variation were T4C (34.2%), C4T (17.1%), A4G (15.8%) and G4A (11.8%). The most common polymorphisms in the mtDNA control region were: 73A4G (100%), 263A4G (100%), 16223C4T (68.6%), 489T4C (50%), 16362T4C (48.6%), 303 poly-C (45.7%), 16519T4C (42.9%), 16189T4C (38.6%), 514-515 del CA (31.4%) and 150C4T (30%). Interestingly, Korean donors showed a high level of length heteroplasmies in both 303 poly-C and 16184 poly-C in the HV2 and HV1 regions, respectively. The length heteroplasmy was further verified by TA cloning (Supplementary Figure 3) .
Chimerism studies were carried out between 14 and 114 days after SCT using seven nuclear DNA markers (STR-D12S391, VNTR-D1S80, STR-D18S51, STR-F13A1, STR-HUM FABP2, STR-HUM RENA-4 and STR-Amelogenin) and seven mtMS markers including direct sequencing of the mtDNA HV region (Supplementary Table 2 ). The median number of informative mtMS markers was two in related patients (range 1-4) and three in unrelated patients (range 1-5). 303 poly-C and 16184 poly-C mtMS were highly informative mtDNA markers, which showed similar informativeness to the nuclear DNA D12S391 and D1S80 markers ( Table 1 ). The sensitivity of the mtMS markers and nuclear DNA STR markers was determined to have the Table 1 Informativeness (%) of the minisatellite markers from mtDNA and nuclear DNA Figure 2) . A study on the accuracy for analysis of 303 poly-C mtDNA marker and nuclear D18S51 STR marker using mixed blood cells in variable concentrations showed that the mtMS marker had a high accuracy compared with those of the nuclear STR marker (Table 2) . Hundreds to thousands of mtDNA copies may exist in a single cell, making it easier to recover and sequence than a single copy of nuclear DNA per cell. In addition, the haploid nature of mtDNA makes it easier to sequence than diploid nuclear DNA. 8 These give rise to the preferential amplification and sequencing of mtDNA. Moreover, mtDNA typing is used primarily in cases in which the nuclear DNA is too degraded or cannot be recovered in sufficient quantities. These facts may explain the reason why the mtMS markers showed higher Chimerism of patient 12 was determined using 303 poly-C and 16184 poly-C of mtMS and D12S391 nuclear DNA marker after allogeneic SCT.
Letters to the Editor sensitivity and informativeness than the nuclear DNA markers (Figure 1 ). Patients with polycythemia vera (PV) are most often treated with phlebotomy and low-dose aspirin therapy alone. Chemotherapeutic agents including hydroxyurea are frequently utilized in patients who are at a high risk of developing thromboses or have disease related systemic symptoms. Such treatment options are unsatisfactory due to the persistent susceptibility of patients to thrombosis and evolution to myelofibrosis and acute leukemia.
Interferon-a (IFN-a) was first shown to be effective in controlling thrombocytosis in patients with essential thrombocythemia (ET) and PV and later shown to be capable of limiting the excess red cell production in patients with PV.
1 Lengfelder et al.
2 summarized the treatment results with IFN-a therapy in 279 patients with PV. In addition to correction of thrombocytosis in approximately 90% of patients, a reduction of splenomegaly was observed in 77% of patients. Pruritus was controlled in 81% of patients, and the frequency of phlebotomy was reduced by 82%. Recombinant interferon-a (rIFN-a) inhibits erythroid progenitors and affects megakaryocyte function, 3, 4 and thus may be a more rational treatment option for patients with PV. Since the initial studies of the use of rIFN-a in treating patients with PV, many reports of its beneficial effects have been published. 1, 2 PV is now treated with rIFN-a with increasing frequency in order to avoid the complications associated with phlebotomy and/or chemotherapy, and to relieve pruritus and other constitutional symptoms. rIFN-a therapy is, however, associated with the need for frequent subcutaneous injections and a relatively high rate of side effects leading to the discontinuation of therapy in 21% of patients with PV and in 25% of patients with ET. 2 To overcome these barriers, pegylated forms of rIFN-a (Peg-rIFN-a) have recently been explored as treatment options for patients with PV. 5, 6 Peg-rIFN-a appears to be safe, non-leukemogenic and well tolerated, although adverse events including fever, thrombocytopenia and headache are not infrequent. A mutation in JAK2 (JAK2V617F) has recently been shown to play a role in the pathogenesis of PV and has been proposed as a mean of monitoring minimal residual disease. 6, 7 In a phase 2 trial of Peg-rIFN-a 2a in PV, Kiladjian et al. 5 performed a prospective sequential quantitative evaluation of the percentage of mutated JAK2 allele (%JAK2V617F) using real-time polymerase chain reaction (PCR). The %JAK2V617F was observed to be decreased in 24 of 27 treated patients. These results confirm the hypothesis that Peg-rIFN-a preferentially targets the malignant clone in PV, and indicates that the %JAK2V617F may prove to be the first useful tool to monitor minimal residual disease in this disorder. 5 In the present study, we report a female patient with PV treated with Peg-rIFN-a 2a (Pegasys, Roche Laboratories, Nutley, NJ) at the dosage of 90 mg weekly. The %JAK2V617F before treatment is shown in Figure 1a . Three weeks following the institution of the therapy, a reduction in blood counts and improvement in symptoms was observed (Figure 1a) . The %JAK2V617F was also gradually decreased and became no longer detectable after 2 months (Figure 1a) . Peg-rIFN-a was discontinued due to the development of mild pancytopenia 3 months after the initiation of the treatment. The molecular complete remission as monitored by JAK2V617F was maintained for an additional 2 months. Simultaneously with the recurrence of the symptoms related to PV, a rapid increase of %JAK2V617F was observed 3 months after discontinuation of Peg-rIFN-a (Figure 1a) .
Clonality assays have been used to determine the contribution of the malignant clone to the blood cell production and a variety of hematological malignancies. 8 rIFN has been previously shown occasionally to be capable of converting clonal hematopoiesis to a polyclonal pattern, thought to be indicative of elimination of the malignant clone. 8 During the period of time when the %JAK2V617F mutation was no longer detected, we performed an assessment of hematopoietic cell clonality using a transcrip-
